Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 20/20 | 0.70 |
| ▸ | PDE1C | Q14123 | 10/20 | 0.70 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | PDE5A | O76074 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1716743 | 0.94 | PDE9A (0.72) | PDE9APDE1CACHEHDAC1HDAC2 | |
| SCHEMBL4516124 | 0.85 | TYK2 (0.54) | PDE9APDE1C | |
| SCHEMBL1717044 | 0.82 | PDE9A (1.00) | PDE9APDE1CHDAC1HDAC2HDAC6 | |
| SCHEMBL15996122 | 0.82 | PDE9A (1.00) | PDE9APDE1CHDAC1HDAC2HDAC6 | |
| SCHEMBL12572064 | 0.81 | PDE9A (0.79) | PDE9APDE1CHDAC1HDAC2HDAC6 | |
| SCHEMBL12572074 | 0.81 | PDE9A (0.79) | PDE9APDE1CHDAC1HDAC2HDAC6 | |
| SCHEMBL13865784 | 0.81 | PDE9A (0.54) | PDE9APDE1C | |
| SCHEMBL13866017 | 0.81 | PDE9A (0.59) | PDE9APDE1C | |
| SCHEMBL12572062 | 0.81 | PDE9A (0.85) | PDE9APDE1CHDAC1HDAC2HDAC6 | |
| SCHEMBL12572133 | 0.80 | PDE9A (0.96) | PDE9APDE1CHDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| WO-2008055959-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | PDE9A 13/4885PDE1C 190/4885ACHE 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.